check_circleStudy Completed

Contraception

GA levonorgestrel intrauterine contraceptive system (LCS) Phase III Study China

Trial purpose

The purpose of this study is to assess the efficacy, safety, bleeding pattern of low dose LNG (12 mg/ 24 hrs), delivered locally by a new intrauterine contraceptive system suitable for use by women 18 to 40 years of age. In addition, pharmacokinetic assessments will be performed.

Key Participants Requirements

Sex

Female

Age

18 - 40 Years

Trial summary

Enrollment Goal
918
Trial Dates
April 2009 - June 2013
Phase
Phase 3
Could I Receive a placebo
No
Products
Skyla (Levonorgestrel, BAY86-5028)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
Royal Brisbane and Women's HospitalHERSTON, 4029, Australia
Completed
Obstetrics & Gynecology Hosp. of Fudan Univ.Shanghai, 200011, China
Completed
Renji Hosp. Shanghai Jiao Tong Univ. School of MedicineShanghai, 200127, China
Completed
Qilu Hosp., Shandong Univ.Jinan, China
Completed
West China 2nd Hosp., of Sichuan Univ.Chengdu, 610041, China
Completed
Drum Tower Hospital of Nanjing University Medical SchoolNanjing, 210008, China
Completed
Zhongda Hosp. affiliated of Southeast Univ.Nanjing, 210009, China
Completed
Cheil general HospitalSeoul, 100-380, Korea, Republic Of
Completed
Sydney Centre for Reproductive Health ReseachAshfield, 2031, Australia
Completed
King Edward Memorial HospitalSubiaco, 6008, Australia
Completed
Royal Womens HospitalParkville, 3052, Australia
Completed
Peking Union Medical College HospitalBeijing, 100730, China
Completed
Peking Univ. First Hosp.Beijing, 100034, China
Completed
Peking University Third HospitalBeijing, 100191, China
Completed
Affiliated Ruijin Hosp. Shanghai Jiaotong Univ. Med SchoolShanghai, 200025, China
Completed
1st Hosp., Chongqing Medical Univ.Chongqing, 400042, China
Completed
2nd Hosp., Chongqing Medical Univ.Chongqing, 400010, China
Completed
Tongji Hosp. of Huazhong Univ. of Science & TechnologyWuhan, 430030, China
Completed
Jiangsu Province CenterNanjing, China
Completed
1st Affiliate Hosp., Dalian Med Univ.Dalian, 116011, China
Completed
1st Affiliated Hosp., Guangzhou Univ. TCMGuangzhou, 510405, China
Completed
Asan Medical CenterSeoul, 138-736, Korea, Republic Of
Completed
Bundang CHA Women's HospitalSungnam-si, 463-712, Korea, Republic Of
Completed
Seoul National University HospitalSeoul, 110-744, Korea, Republic Of
Completed
Severance Hospital, Yonsei University College of MedicineSeoul, 120-752, Korea, Republic Of

Primary Outcome

  • Primary efficacy variable is the occurrence of pregnancy, the Pearl Index (PI) is defined as the number of pregnancies per 100 woman years.
    date_rangeTime Frame:
    3 years
    enhanced_encryption
    Safety Issue:
    no

Secondary Outcome

  • LCS expulsion rate
    date_rangeTime Frame:
    3 years
    enhanced_encryption
    Safety Issue:
    no
  • Discontinuation rates
    date_rangeTime Frame:
    3 years
    enhanced_encryption
    Safety Issue:
    no
  • Adverse events
    date_rangeTime Frame:
    3 years
    enhanced_encryption
    Safety Issue:
    yes
  • Laboratory tests
    date_rangeTime Frame:
    3 years
    enhanced_encryption
    Safety Issue:
    yes

Trial design

Multi-center, open label, single arm study to assess efficacy, safety, bleeding pattern and pharmacokinetics of the ultra low dose levonorgestrel intrauterine contraceptive system (LCS) for a maximum of 3 years in women 18 to 40 years of age
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Non-randomized
Blinding
Open Label
Assignment
Single Group Assignment
Trial Arms
1